Iklan
Iklan
Coxiron

Coxiron

etoricoxib

Manufacturer:

Ferron
Concise Prescribing Info
Contents
Etoricoxib
Indications/Uses
Symptomatic relief of OA. Relief of chronic musculoskeletal pain & acute pain associated w/ dental surgery.
Dosage/Direction for Use
OA & chronic musculoskeletal pain Recommended dose: 60 mg once daily. Acute pain associated w/ dental surgery Recommended dose: 120 mg once daily & used only for acute symptomatic period. Moderate hepatic insufficiency (Child-Pugh score 7-9) Max: 60 mg every other day. May consider administration of 30 mg once daily. Mild hepatic insufficiency (Child-Pugh score 5-6) Max: 60 mg once daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. CHF (NYHA II-IV). Established ischemic heart disease, peripheral artery disease &/or cerebrovascular disease (including patients who have recently undergone CABG surgery or angioplasty).
Special Precautions
Discontinue use if persistently abnormal LFTs are detected. Greater risk of serious CV thrombotic events, MI & stroke in patients w/ known CV disease or its risk factors. Concurrent use of aspirin & NSAIDs. Increased MI & stroke incidence when used for pain in the 1st 10-14 days following CABG surgery. Concomitant use of thiazides or loop diuretics; oral steroids or anticoagulants. Patients w/ HTN; closely monitor BP during NSAID treatment initiation & throughout the course of therapy. Patients w/ fluid retention or heart failure. Patients w/ history of PUD &/or GI bleeding. Immediately evaluate & give additional treatment if serious GI effects are suspected; considered alternative therapy that does not include NSAIDs for high-risk patient. Dehydration; rehydrate patients prior to starting therapy. Possible fluid retention, edema or HTN exacerbation in patients w/ pre-existing edema, HTN or heart failure. Possible more frequent & severe HTN particularly at high doses; consider alternative treatment if BP rises significantly. Patients w/ medical history of ischemic heart disease. Possible development of GI ulcers/ulcer complications. Patients who have previously experienced acute asthmatic attacks, urticaria or rhinitis. May mask fever. ALT &/or AST elevations. Not recommended in patients w/ advanced renal disease. Close monitoring of renal function in patients w/ estimated CrCl <30 mL/min. Pre-existing significantly impaired renal function, uncompensated heart failure or cirrhosis; consider monitoring renal function. Pregnancy (1st & 2nd trimesters). Lactation. Childn. Elderly >65 yr. Debilitated patients.
Adverse Reactions
Asthenia/fatigue, dizziness, lower extremity edema, HTN, dyspepsia, heartburn, nausea, headache, increased ALT & AST.
Drug Interactions
Increased prothrombin time INR in patients stabilized on chronic warfarin therapy. Decreased AUC w/ rifampin. Increased plasma conc & reduced renal clearance of MTX. May diminish antihypertensive effect of diuretics, ACE inhibitors & AIIAs. May increase plasma lithium levels. Increased rate of GI ulceration or other complications w/ low-dose aspirin. Increased steady-state AUC0-24hr of ethinyl estradiol; unconjugated estrone, equilin & 17-β-estradiol.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.
Presentation/Packing
Form
Coxiron FC tab 120 mg
Packing/Price
3 × 10's
Form
Coxiron FC tab 60 mg
Packing/Price
3 × 10's
Form
Coxiron FC tab 90 mg
Packing/Price
3 × 10's
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan